Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Influenza

Free Subscription Articles published in Cell Retrieve available abstracts of 206 articles: HTML format

Single Articles

July 2022
1. TUEKPRAKHON A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, et al
   Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
   Cell. 2022;185:2422-2433.
   PubMed     Abstract available
   
   
   
2. KAO J, Frankland PW
   COVID fog demystified.
   Cell. 2022;185:2391-2393.
   PubMed     Abstract available
   
   
   
3. FERNANDEZ-CASTANEDA A, Lu P, Geraghty AC, Song E, et al
   Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation.
   Cell. 2022;185:2452-2468.
   PubMed     Abstract available
   
   
   
4. ZHANG Z, Mateus J, Coelho CH, Dan JM, et al
   Humoral and cellular immune memory to four COVID-19 vaccines.
   Cell. 2022;185:2434-2451.
   PubMed     Abstract available
   
   
   June 2022
5. XU K, Gao P, Liu S, Lu S, et al
   Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.
   Cell. 2022;185:2265-2278.
   PubMed     Abstract available
   
   
   
6. NUTALAI R, Zhou D, Tuekprakhon A, Ginn HM, et al
   Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
   Cell. 2022;185:2116-2131.
   PubMed     Abstract available
   
   
   
7. YAMASOBA D, Kimura I, Nasser H, Morioka Y, et al
   Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
   Cell. 2022;185:2103-2115.
   PubMed     Abstract available
   
   
   
8. CHATURVEDI S, Pablo M, Wolf M, Rosas-Rivera D, et al
   Disrupting autorepression circuitry generates "open-loop lethality" to yield escape-resistant antiviral agents.
   Cell. 2022;185:2086-2102.
   PubMed     Abstract available
   
   
   May 2022
9. YEUNG ML, Teng JLL, Yuen KY
   Response to Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity.
   Cell. 2022;185:1840-1841.
   PubMed    
   
   
   
10. BATLLE D, Monteil V, Garreta E, Hassler L, et al
    Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity.
    Cell. 2022;185:1837-1839.
    PubMed    
    
    
    
11. GOEL RR, Painter MM, Lundgreen KA, Apostolidis SA, et al
    Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine.
    Cell. 2022;185:1875-1887.
    PubMed     Abstract available
    
    
    April 2022
12. YING B, Scheaffer SM, Whitener B, Liang CY, et al
    Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
    Cell. 2022;185:1572-1587.
    PubMed     Abstract available
    
    
    
13. GAGNE M, Moliva JI, Foulds KE, Andrew SF, et al
    mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.
    Cell. 2022;185:1556-1571.
    PubMed     Abstract available
    
    
    
14. SERVELLITA V, Syed AM, Morris MK, Brazer N, et al
    Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
    Cell. 2022;185:1539-1548.
    PubMed     Abstract available
    
    
    
15. CHANDRASHEKAR A, Yu J, McMahan K, Jacob-Dolan C, et al
    Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.
    Cell. 2022;185:1549-1555.
    PubMed     Abstract available
    
    
    
16. RODDA LB, Morawski PA, Pruner KB, Fahning ML, et al
    Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity.
    Cell. 2022;185:1588-1601.
    PubMed     Abstract available
    
    
    
17. 
    Bringing research to the intensive care setting.
    Cell. 2022;185:1275-1278.
    PubMed     Abstract available
    
    
    
18. 
    Learning lessons from lipids to make COVID-19 vaccines.
    Cell. 2022;185:1279-1282.
    PubMed     Abstract available
    
    
    
19. LI C, Zhan W, Yang Z, Tu C, et al
    Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.
    Cell. 2022;185:1389-1401.
    PubMed     Abstract available
    
    
    
20. YEN M, Ren J, Liu Q, Glassman CR, et al
    Facile discovery of surrogate cytokine agonists.
    Cell. 2022;185:1414-1430.
    PubMed     Abstract available
    
    
    
21. QU L, Yi Z, Shen Y, Lin L, et al
    Circular RNA vaccines against SARS-CoV-2 and emerging variants.
    Cell. 2022 Apr 1. pii: S0092-8674(22)00394-4. doi: 10.1016/j.cell.2022.
    PubMed     Abstract available
    
    
    March 2022
22. TANGYE SG, Burnett DL, Bull RA
    Getting to the (germinal) center of humoral immune responses to SARS-CoV-2.
    Cell. 2022;185:945-948.
    PubMed     Abstract available
    
    
    
23. ZAZHYTSKA M, Kodra A, Hoagland DA, Frere J, et al
    Non-cell-autonomous disruption of nuclear architecture as a potential cause of COVID-19-induced anosmia.
    Cell. 2022;185:1052-1064.
    PubMed     Abstract available
    
    
    
24. ROLTGEN K, Nielsen SCA, Silva O, Younes SF, et al
    Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.
    Cell. 2022;185:1025-1040.
    PubMed     Abstract available
    
    
    
25. 
    A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
    Cell. 2022;185:916-938.
    PubMed     Abstract available
    
    
    
26. SU Y, Yuan D, Chen DG, Ng RH, et al
    Multiple early factors anticipate post-acute COVID-19 sequelae.
    Cell. 2022;185:881-895.
    PubMed     Abstract available
    
    
    
27. AFKHAMI S, D'Agostino MR, Zhang A, Stacey HD, et al
    Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
    Cell. 2022;185:896-915.
    PubMed     Abstract available
    
    
    
28. TARKE A, Coelho CH, Zhang Z, Dan JM, et al
    SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.
    Cell. 2022;185:847-859.
    PubMed     Abstract available
    
    
    
29. CUI Z, Liu P, Wang N, Wang L, et al
    Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron.
    Cell. 2022;185:860-871.
    PubMed     Abstract available
    
    
    February 2022
30. BORRIELLO F, Poli V, Shrock E, Spreafico R, et al
    An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity.
    Cell. 2022;185:614-629.
    PubMed     Abstract available
    
    
    
31. MUDD PA, Minervina AA, Pogorelyy MV, Turner JS, et al
    SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.
    Cell. 2022;185:603-613.
    PubMed     Abstract available
    
    
    
32. WESEMANN DR
    Omicron's message on vaccines: Boosting begets breadth.
    Cell. 2022;185:411-413.
    PubMed     Abstract available
    
    
    
33. SIDDLE KJ, Krasilnikova LA, Moreno GK, Schaffner SF, et al
    Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak.
    Cell. 2022;185:485-492.
    PubMed     Abstract available
    
    
    
34. GEORG P, Astaburuaga-Garcia R, Bonaguro L, Brumhard S, et al
    Complement activation induces excessive T cell cytotoxicity in severe COVID-19.
    Cell. 2022;185:493-512.
    PubMed     Abstract available
    
    
    
35. HOFFMANN M, Kruger N, Schulz S, Cossmann A, et al
    The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
    Cell. 2022;185:447-456.
    PubMed     Abstract available
    
    
    
36. COLLINS F
    Francis Collins: Reflections on being the NIH Director.
    Cell. 2022;185:401-406.
    PubMed     Abstract available
    
    
    December 2021
37. GRUBAUGH ND, Cobey S
    Of variants and vaccines.
    Cell. 2021;184:6222-6223.
    PubMed     Abstract available
    
    
    
38. TERMINI CM, Rutaganira FUN, Palavicino-Maggio CB, Spriggs CC, et al
    Using virtual interviewing to create a more accessible hybrid academic job market.
    Cell. 2021;184:6217-6221.
    PubMed     Abstract available
    
    
    
39. WENDISCH D, Dietrich O, Mari T, von Stillfried S, et al
    SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.
    Cell. 2021;184:6243-6261.
    PubMed     Abstract available
    
    
    
40. BUSHMAN M, Kahn R, Taylor BP, Lipsitch M, et al
    Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape.
    Cell. 2021;184:6229-6242.
    PubMed     Abstract available
    
    
    
41. BRIAND SC, Cinelli M, Nguyen T, Lewis R, et al
    Infodemics: A new challenge for public health.
    Cell. 2021;184:6010-6014.
    PubMed     Abstract available
    
    
    
42. XIAO Y, Lidsky PV, Shirogane Y, Aviner R, et al
    A defective viral genome strategy elicits broad protective immunity against respiratory viruses.
    Cell. 2021;184:6037-6051.
    PubMed     Abstract available
    
    
    
43. CHATURVEDI S, Vasen G, Pablo M, Chen X, et al
    Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance.
    Cell. 2021;184:6022-6036.
    PubMed     Abstract available
    
    
    November 2021
44. KHAN M, Yoo SJ, Clijsters M, Backaert W, et al
    Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb.
    Cell. 2021;184:5932-5949.
    PubMed     Abstract available
    
    
    
45. KUMAR S, Javed R, Mudd M, Pallikkuth S, et al
    Mammalian hybrid pre-autophagosomal structure HyPAS generates autophagosomes.
    Cell. 2021;184:5950-5969.
    PubMed     Abstract available
    
    
    
46. PAYNE RP, Longet S, Austin JA, Skelly DT, et al
    Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
    Cell. 2021;184:5699-5714.
    PubMed     Abstract available
    
    
    October 2021
47. CROSS G, Ho JSY, Zacharias W, Jeyasekharan AD, et al
    Emergency drug use in a pandemic: Harsh lessons from COVID-19.
    Cell. 2021;184:5497-5500.
    PubMed     Abstract available
    
    
    
48. 
    Persistent progress.
    Cell. 2021;184:5293-5296.
    PubMed     Abstract available
    
    
    
49. SHAPIRO L, Losick R
    Delivering the message: How a novel technology enabled the rapid development of effective vaccines.
    Cell. 2021;184:5271-5274.
    PubMed     Abstract available
    
    
    September 2021
50. MARTIN DP, Weaver S, Tegally H, San JE, et al
    The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages.
    Cell. 2021;184:5189-5200.
    PubMed     Abstract available
    
    
    
51. CEVIK M, Grubaugh ND, Iwasaki A, Openshaw P, et al
    COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
    Cell. 2021;184:5077-5081.
    PubMed     Abstract available
    
    
    
52. JACKSON B, Boni MF, Bull MJ, Colleran A, et al
    Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic.
    Cell. 2021;184:5179-5188.
    PubMed     Abstract available
    
    
    
53. 
    Building and supporting identity in peer review.
    Cell. 2021;184:5071-5072.
    PubMed    
    
    
    
54. ZELLER M, Gangavarapu K, Anderson C, Smither AR, et al
    Emergence of an early SARS-CoV-2 epidemic in the United States.
    Cell. 2021;184:4939-4952.
    PubMed     Abstract available
    
    
    
55. SPOSITO B, Broggi A, Pandolfi L, Crotta S, et al
    The interferon landscape along the respiratory tract impacts the severity of COVID-19.
    Cell. 2021;184:4953-4968.
    PubMed     Abstract available
    
    
    
56. HOLMES EC, Goldstein SA, Rasmussen AL, Robertson DL, et al
    The origins of SARS-CoV-2: A critical review.
    Cell. 2021;184:4848-4856.
    PubMed     Abstract available
    
    
    
57. ZIEGLER CGK, Miao VN, Owings AH, Navia AW, et al
    Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19.
    Cell. 2021;184:4713-4733.
    PubMed     Abstract available
    
    
    August 2021
58. KARLSSON EA, Duong V
    The continuing search for the origins of SARS-CoV-2.
    Cell. 2021;184:4373-4374.
    PubMed     Abstract available
    
    
    
59. KANG L, He G, Sharp AK, Wang X, et al
    A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation.
    Cell. 2021;184:4392-4400.
    PubMed     Abstract available
    
    
    
60. NATHAN A, Rossin EJ, Kaseke C, Park RJ, et al
    Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.
    Cell. 2021;184:4401-4413.
    PubMed     Abstract available
    
    
    
61. ZHOU H, Ji J, Chen X, Bi Y, et al
    Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses.
    Cell. 2021;184:4380-4391.
    PubMed     Abstract available
    
    
    
62. LIU C, Ginn HM, Dejnirattisai W, Supasa P, et al
    Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
    Cell. 2021;184:4220-4236.
    PubMed     Abstract available
    
    
    
63. LI D, Edwards RJ, Manne K, Martinez DR, et al
    In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
    Cell. 2021;184:4203-4219.
    PubMed     Abstract available
    
    
    July 2021
64. RESCIGNO M
    Unraveling the long-term effect of influenza vaccines.
    Cell. 2021;184:3845-3847.
    PubMed     Abstract available
    
    
    
65. WEINGARTEN-GABBAY S, Klaeger S, Sarkizova S, Pearlman LR, et al
    Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs.
    Cell. 2021;184:3962-3980.
    PubMed     Abstract available
    
    
    
66. COPIN R, Baum A, Wloga E, Pascal KE, et al
    The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
    Cell. 2021;184:3949-3961.
    PubMed     Abstract available
    
    
    June 2021
67. YAN L, Yang Y, Li M, Zhang Y, et al
    Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading.
    Cell. 2021;184:3474-3485.
    PubMed     Abstract available
    
    
    
68. LIU K, Pan X, Li L, Yu F, et al
    Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species.
    Cell. 2021;184:3438-3451.
    PubMed     Abstract available
    
    
    
69. LIU Y, Soh WT, Kishikawa JI, Hirose M, et al
    An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
    Cell. 2021;184:3452-3466.
    PubMed     Abstract available
    
    
    
70. HE X, Chandrashekar A, Zahn R, Wegmann F, et al
    Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
    Cell. 2021;184:3467-3473.
    PubMed     Abstract available
    
    
    
71. HAO Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, et al
    Integrated analysis of multimodal single-cell data.
    Cell. 2021;184:3573-3587.
    PubMed     Abstract available
    
    
    
72. DENG X, Garcia-Knight MA, Khalid MM, Servellita V, et al
    Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
    Cell. 2021;184:3426-3437.
    PubMed     Abstract available
    
    
    
73. WIMMERS F, Donato M, Kuo A, Ashuach T, et al
    The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination.
    Cell. 2021 Jun 22. pii: S0092-8674(21)00692-9. doi: 10.1016/j.cell.2021.
    PubMed     Abstract available
    
    
    
74. CORTI D, Purcell LA, Snell G, Veesler D, et al
    Tackling COVID-19 with neutralizing monoclonal antibodies.
    Cell. 2021;184:3086-3108.
    PubMed     Abstract available
    
    
    
75. SCHEID JF, Barnes CO, Eraslan B, Hudak A, et al
    B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.
    Cell. 2021;184:3205-3221.
    PubMed     Abstract available
    
    
    
76. ASARNOW D, Wang B, Lee WH, Hu Y, et al
    Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
    Cell. 2021;184:3192-3204.
    PubMed     Abstract available
    
    
    May 2021
77. BAUMER Y, Powell-Wiley TM
    Interdisciplinary approaches are fundamental to decode the biology of adversity.
    Cell. 2021;184:2797-2801.
    PubMed     Abstract available
    
    
    
78. GARRETT ME, Galloway J, Chu HY, Itell HL, et al
    High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies.
    Cell. 2021;184:2927-2938.
    PubMed     Abstract available
    
    
    
79. DEJNIRATTISAI W, Zhou D, Supasa P, Liu C, et al
    Antibody evasion by the P.1 strain of SARS-CoV-2.
    Cell. 2021;184:2939-2954.
    PubMed     Abstract available
    
    
    
80. WILLIAMS WB, Meyerhoff RR, Edwards RJ, Li H, et al
    Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.
    Cell. 2021 May 18. pii: S0092-8674(21)00577-8. doi: 10.1016/j.cell.2021.
    PubMed     Abstract available
    
    
    
81. ALPERT T, Brito AF, Lasek-Nesselquist E, Rothman J, et al
    Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States.
    Cell. 2021;184:2595-2604.
    PubMed     Abstract available
    
    
    
82. WASHINGTON NL, Gangavarapu K, Zeller M, Bolze A, et al
    Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States.
    Cell. 2021;184:2587-2594.
    PubMed     Abstract available
    
    
    
83. HO JSY, Mok BW, Campisi L, Jordan T, et al
    TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
    Cell. 2021;184:2618-2632.
    PubMed     Abstract available
    
    
    
84. CLARK SA, Clark LE, Pan J, Coscia A, et al
    SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms.
    Cell. 2021;184:2605-2617.
    PubMed     Abstract available
    
    
    
85. QIU X, Hanage WP, Taylor BP
    Coming to America: Genomic surveillance and how B.1.1.7 arrived in the US.
    Cell. 2021;184:2532-2534.
    PubMed     Abstract available
    
    
    April 2021
86. LEBLANC EV, Colpitts CC
    SARS-CoV-2 RNA: Exclusive friends and common foes.
    Cell. 2021;184:2276-2278.
    PubMed     Abstract available
    
    
    
87. BOEHM JS
    The power of parent scientists.
    Cell. 2021;184:2263-2270.
    PubMed     Abstract available
    
    
    
88. HOFFMANN M, Arora P, Gross R, Seidel A, et al
    SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
    Cell. 2021;184:2384-2393.
    PubMed     Abstract available
    
    
    
89. SURYADEVARA N, Shrihari S, Gilchuk P, VanBlargan LA, et al
    Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.
    Cell. 2021;184:2316-2331.
    PubMed     Abstract available
    
    
    
90. FABIUS JM, Krogan NJ
    Creating collaboration by breaking down scientific barriers.
    Cell. 2021;184:2271-2275.
    PubMed     Abstract available
    
    
    
91. MCCALLUM M, De Marco A, Lempp FA, Tortorici MA, et al
    N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
    Cell. 2021;184:2332-2347.
    PubMed     Abstract available
    
    
    
92. GARCIA-BELTRAN WF, Lam EC, St Denis K, Nitido AD, et al
    Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
    Cell. 2021;184:2372-2383.
    PubMed     Abstract available
    
    
    
93. FLYNN RA, Belk JA, Qi Y, Yasumoto Y, et al
    Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions.
    Cell. 2021;184:2394-2411.
    PubMed     Abstract available
    
    
    
94. ZHOU D, Dejnirattisai W, Supasa P, Liu C, et al
    Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
    Cell. 2021;184:2348-2361.
    PubMed     Abstract available
    
    
    
95. 
    The origins of viral infection sleuth.
    Cell. 2021;184:1960-1961.
    PubMed     Abstract available
    
    
    
96. SCHNEIDER JL, Rowe JH, Garcia-de-Alba C, Kim CF, et al
    The aging lung: Physiology, disease, and immunity.
    Cell. 2021;184:1990-2019.
    PubMed     Abstract available
    
    
    
97. MILLS RJ, Humphrey SJ, Fortuna PRJ, Lor M, et al
    BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.
    Cell. 2021;184:2167-2182.
    PubMed     Abstract available
    
    
    
98. DEJNIRATTISAI W, Zhou D, Ginn HM, Duyvesteyn HME, et al
    The antigenic anatomy of SARS-CoV-2 receptor binding domain.
    Cell. 2021;184:2183-2200.
    PubMed     Abstract available
    
    
    
99. SUPASA P, Zhou D, Dejnirattisai W, Liu C, et al
    Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
    Cell. 2021;184:2201-2211.
    PubMed     Abstract available
    
    
    
100. YEUNG ML, Teng JLL, Jia L, Zhang C, et al
     Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.
     Cell. 2021;184:2212-2228.
     PubMed     Abstract available
     
     
     
101. ZHANG X, Liu Y, Liu J, Bailey AL, et al
     A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence.
     Cell. 2021;184:2229-2238.
     PubMed     Abstract available
     
     
     
102. PEIRIS JSM
     One world, one health.
     Cell. 2021;184:1956-1959.
     PubMed     Abstract available
     
     
     
103. SCHULTZE JL, Aschenbrenner AC
     COVID-19 and the human innate immune system.
     Cell. 2021;184:1671-1692.
     PubMed     Abstract available
     
     
     
104. YU B, Qi Y, Li R, Shi Q, et al
     B cell-specific XIST complex enforces X-inactivation and restrains atypical B cells.
     Cell. 2021;184:1790-1803.
     PubMed     Abstract available
     
     
     
105. LIU C, Martins AJ, Lau WW, Rachmaninoff N, et al
     Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19.
     Cell. 2021;184:1836-1857.
     PubMed     Abstract available
     
     
     
106. WINKLER ES, Gilchuk P, Yu J, Bailey AL, et al
     Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.
     Cell. 2021;184:1804-1820.
     PubMed     Abstract available
     
     
     
107. ANDREANO E, Nicastri E, Paciello I, Pileri P, et al
     Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
     Cell. 2021;184:1821-1835.
     PubMed     Abstract available
     
     
     
108. REN X, Wen W, Fan X, Hou W, et al
     COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas.
     Cell. 2021;184:1895-1913.
     PubMed     Abstract available
     
     
     
109. SUN L, Li P, Ju X, Rao J, et al
     In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs.
     Cell. 2021;184:1865-1883.
     PubMed     Abstract available
     
     
     
110. ANDERSON EM, Goodwin EC, Verma A, Arevalo CP, et al
     Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.
     Cell. 2021;184:1858-1864.
     PubMed     Abstract available
     
     
     March 2021
111. GEBRE MS, Brito LA, Tostanoski LH, Edwards DK, et al
     Novel approaches for vaccine development.
     Cell. 2021;184:1589-1603.
     PubMed     Abstract available
     
     
     
112. SANDRONE S, Scott G, Anderson WJ, Musunuru K, et al
     Active learning-based STEM education for in-person and online learning.
     Cell. 2021;184:1409-1414.
     PubMed     Abstract available
     
     
     
113. 
     Scientific misinformation: A perfect storm, missteps, and moving forward.
     Cell. 2021;184:1402-1406.
     PubMed     Abstract available
     
     
     
114. TOPOL EJ
     Messenger RNA vaccines against SARS-CoV-2.
     Cell. 2021;184:1401.
     PubMed     Abstract available
     
     
     
115. PILLON NJ, Loos RJF, Marshall SM, Zierath JR, et al
     Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care.
     Cell. 2021;184:1530-1544.
     PubMed     Abstract available
     
     
     
116. MANN ME, Hall LJ, Dulvy NK
     Scientific impact in a changing world.
     Cell. 2021;184:1407-1408.
     PubMed     Abstract available
     
     
     
117. THOMSON EC, Rosen LE, Shepherd JG, Spreafico R, et al
     Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.
     Cell. 2021;184:1171-1187.
     PubMed     Abstract available
     
     
     
118. GRUBAUGH ND, Hodcroft EB, Fauver JR, Phelan AL, et al
     Public health actions to control new SARS-CoV-2 variants.
     Cell. 2021;184:1127-1132.
     PubMed     Abstract available
     
     
     
119. BROUWER PJM, Brinkkemper M, Maisonnasse P, Dereuddre-Bosquet N, et al
     Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.
     Cell. 2021;184:1188-1200.
     PubMed     Abstract available
     
     
     
120. SOKAL A, Chappert P, Barba-Spaeth G, Roeser A, et al
     Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.
     Cell. 2021;184:1201-1213.
     PubMed     Abstract available
     
     
     February 2021
121. LI Q, Nie J, Wu J, Zhang L, et al
     SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.
     Cell. 2021 Feb 23. pii: S0092-8674(21)00231-2. doi: 10.1016/j.cell.2021.
     PubMed     Abstract available
     
     
     
122. SETTE A, Crotty S
     Adaptive immunity to SARS-CoV-2 and COVID-19.
     Cell. 2021;184:861-880.
     PubMed     Abstract available
     
     
     
123. NIE X, Qian L, Sun R, Huang B, et al
     Multi-organ proteomic landscape of COVID-19 autopsies.
     Cell. 2021;184:775-791.
     PubMed     Abstract available
     
     
     
124. ATYEO C, Pullen KM, Bordt EA, Fischinger S, et al
     Compromised SARS-CoV-2-specific placental antibody transfer.
     Cell. 2021;184:628-642.
     PubMed     Abstract available
     
     
     January 2021
125. GARCIA-BELTRAN WF, Lam EC, Astudillo MG, Yang D, et al
     COVID-19-neutralizing antibodies predict disease severity and survival.
     Cell. 2021;184:476-488.
     PubMed     Abstract available
     
     
     
126. HOANG TN, Pino M, Boddapati AK, Viox EG, et al
     Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
     Cell. 2021;184:460-475.
     PubMed     Abstract available
     
     
     
127. 
     What happens next.
     Cell. 2021;184:291-292.
     PubMed    
     
     
     
128. HOFFMANN HH, Schneider WM, Rozen-Gagnon K, Miles LA, et al
     TMEM41B Is a Pan-flavivirus Host Factor.
     Cell. 2021;184:133-148.
     PubMed     Abstract available
     
     
     
129. WANG R, Simoneau CR, Kulsuptrakul J, Bouhaddou M, et al
     Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses.
     Cell. 2021;184:106-119.
     PubMed     Abstract available
     
     
     
130. RODDA LB, Netland J, Shehata L, Pruner KB, et al
     Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.
     Cell. 2021;184:169-183.
     PubMed     Abstract available
     
     
     
131. KARKI R, Sharma BR, Tuladhar S, Williams EP, et al
     Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes.
     Cell. 2021;184:149-168.
     PubMed     Abstract available
     
     
     
132. VOLZ E, Hill V, McCrone JT, Price A, et al
     Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.
     Cell. 2021;184:64-75.
     PubMed     Abstract available
     
     
     
133. DANILOSKI Z, Jordan TX, Wessels HH, Hoagland DA, et al
     Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells.
     Cell. 2021;184:92-105.
     PubMed     Abstract available
     
     
     
134. WEI J, Alfajaro MM, DeWeirdt PC, Hanna RE, et al
     Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection.
     Cell. 2021;184:76-91.
     PubMed     Abstract available
     
     
     December 2020
135. AVANZATO VA, Matson MJ, Seifert SN, Pryce R, et al
     Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.
     Cell. 2020;183:1901-1912.
     PubMed     Abstract available
     
     
     
136. ZOHAR T, Loos C, Fischinger S, Atyeo C, et al
     Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality.
     Cell. 2020;183:1508-1519.
     PubMed     Abstract available
     
     
     
137. SU Y, Chen D, Yuan D, Lausted C, et al
     Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.
     Cell. 2020;183:1479-1495.
     PubMed     Abstract available
     
     
     
138. CHEN Y, Zuiani A, Fischinger S, Mullur J, et al
     Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production.
     Cell. 2020;183:1496-1507.
     PubMed     Abstract available
     
     
     
139. GHOSH S, Dellibovi-Ragheb TA, Kerviel A, Pak E, et al
     beta-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway.
     Cell. 2020;183:1520-1535.
     PubMed     Abstract available
     
     
     November 2020
140. WALLS AC, Fiala B, Schafer A, Wrenn S, et al
     Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
     Cell. 2020;183:1367-1382.
     PubMed     Abstract available
     
     
     
141. MECKIFF BJ, Ramirez-Suastegui C, Fajardo V, Chee SJ, et al
     Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19.
     Cell. 2020;183:1340-1353.
     PubMed     Abstract available
     
     
     
142. BANERJEE AK, Blanco MR, Bruce EA, Honson DD, et al
     SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses.
     Cell. 2020;183:1325-1339.
     PubMed     Abstract available
     
     
     
143. AID M, Busman-Sahay K, Vidal SJ, Maliga Z, et al
     Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques.
     Cell. 2020;183:1354-1366.
     PubMed     Abstract available
     
     
     
144. KREYE J, Reincke SM, Kornau HC, Sanchez-Sendin E, et al
     A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
     Cell. 2020;183:1058-1069.
     PubMed     Abstract available
     
     
     
145. LEIST SR, Dinnon KH 3rd, Schafer A, Tse LV, et al
     A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice.
     Cell. 2020;183:1070-1085.
     PubMed     Abstract available
     
     
     
146. RYDYZNSKI MODERBACHER C, Ramirez SI, Dan JM, Grifoni A, et al
     Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
     Cell. 2020;183:996-1012.
     PubMed     Abstract available
     
     
     
147. PICCOLI L, Park YJ, Tortorici MA, Czudnochowski N, et al
     Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
     Cell. 2020;183:1024-1042.
     PubMed     Abstract available
     
     
     
148. GRUBER CN, Patel RS, Trachtman R, Lepow L, et al
     Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C).
     Cell. 2020;183:982-995.
     PubMed     Abstract available
     
     
     
149. CLAUSEN TM, Sandoval DR, Spliid CB, Pihl J, et al
     SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
     Cell. 2020;183:1043-1057.
     PubMed     Abstract available
     
     
     
150. CONSIGLIO CR, Cotugno N, Sardh F, Pou C, et al
     The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19.
     Cell. 2020;183:968-981.
     PubMed     Abstract available
     
     
     October 2020
151. YURKOVETSKIY L, Wang X, Pascal KE, Tomkins-Tinch C, et al
     Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.
     Cell. 2020;183:739-751.
     PubMed     Abstract available
     
     
     
152. MUKHERJEE S
     Before Virus, After Virus: A Reckoning.
     Cell. 2020;183:308-314.
     PubMed     Abstract available
     
     
     
153. IWASAKI A, Omer SB
     Why and How Vaccines Work.
     Cell. 2020;183:290-295.
     PubMed     Abstract available
     
     
     
154. GOLDSTEIN JL
     The Spanish 1918 Flu and the COVID-19 Disease: The Art of Remembering and Foreshadowing Pandemics.
     Cell. 2020;183:285-289.
     PubMed     Abstract available
     
     
     
155. LI W, Schafer A, Kulkarni SS, Liu X, et al
     High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models.
     Cell. 2020;183:429-441.
     PubMed     Abstract available
     
     
     
156. SEKINE T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, et al
     Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.
     Cell. 2020;183:158-168.
     PubMed     Abstract available
     
     
     
157. AU L, Boos LA, Swerdlow A, Byrne F, et al
     Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study.
     Cell. 2020;183:4-10.
     PubMed     Abstract available
     
     
     
158. CANETE PF, Vinuesa CG
     COVID-19 Makes B Cells Forget, but T Cells Remember.
     Cell. 2020;183:13-15.
     PubMed     Abstract available
     
     
     
159. HASSAN AO, Kafai NM, Dmitriev IP, Fox JM, et al
     A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.
     Cell. 2020;183:169-184.
     PubMed     Abstract available
     
     
     
160. IADECOLA C, Anrather J, Kamel H
     Effects of COVID-19 on the Nervous System.
     Cell. 2020;183:16-27.
     PubMed     Abstract available
     
     
     
161. KANEKO N, Kuo HH, Boucau J, Farmer JR, et al
     Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19.
     Cell. 2020;183:143-157.
     PubMed     Abstract available
     
     
     September 2020
162. SILVIN A, Chapuis N, Dunsmore G, Goubet AG, et al
     Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.
     Cell. 2020;182:1401-1418.
     PubMed     Abstract available
     
     
     
163. COLUBRI A, Kemball M, Sani K, Boehm C, et al
     Preventing Outbreaks through Interactive, Experiential Real-Life Simulations.
     Cell. 2020;182:1366-1371.
     PubMed     Abstract available
     
     
     
164. SCHULTE-SCHREPPING J, Reusch N, Paclik D, Bassler K, et al
     Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment.
     Cell. 2020;182:1419-1440.
     PubMed     Abstract available
     
     
     
165. DU S, Cao Y, Zhu Q, Yu P, et al
     Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
     Cell. 2020 Sep 14. pii: S0092-8674(20)31232-0. doi: 10.1016/j.cell.2020.
     PubMed     Abstract available
     
     
     
166. MORENS DM, Fauci AS
     Emerging Pandemic Diseases: How We Got to COVID-19.
     Cell. 2020;182:1077-1092.
     PubMed     Abstract available
     
     
     August 2020
167. GRUBAUGH ND, Hanage WP, Rasmussen AL
     Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear.
     Cell. 2020;182:794-795.
     PubMed     Abstract available
     
     
     
168. KORBER B, Fischer WM, Gnanakaran S, Yoon H, et al
     Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
     Cell. 2020;182:812-827.
     PubMed     Abstract available
     
     
     
169. KREER C, Zehner M, Weber T, Ercanoglu MS, et al
     Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
     Cell. 2020;182:843-854.
     PubMed     Abstract available
     
     
     
170. BARNES CO, West AP Jr, Huey-Tubman KE, Hoffmann MAG, et al
     Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
     Cell. 2020;182:828-842.
     PubMed     Abstract available
     
     
     
171. GEITMANN A
     Travel Less. Make It Worthwhile.
     Cell. 2020;182:790-793.
     PubMed     Abstract available
     
     
     
172. WANG H, Zhang Y, Huang B, Deng W, et al
     Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
     Cell. 2020;182:713-721.
     PubMed     Abstract available
     
     
     
173. DAI L, Zheng T, Xu K, Han Y, et al
     A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
     Cell. 2020;182:722-733.
     PubMed     Abstract available
     
     
     
174. BOUHADDOU M, Memon D, Meyer B, White KM, et al
     The Global Phosphorylation Landscape of SARS-CoV-2 Infection.
     Cell. 2020;182:685-712.
     PubMed     Abstract available
     
     
     
175. SUN J, Zhuang Z, Zheng J, Li K, et al
     Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.
     Cell. 2020;182:734-743.
     PubMed     Abstract available
     
     
     
176. HASSAN AO, Case JB, Winkler ES, Thackray LB, et al
     A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.
     Cell. 2020;182:744-753.
     PubMed     Abstract available
     
     
     July 2020
177. EINAV T, Gentles LE, Bloom JD
     SnapShot: Influenza by the Numbers.
     Cell. 2020;182:532-532.
     PubMed     Abstract available
     
     
     
178. JIANG RD, Liu MQ, Chen Y, Shan C, et al
     Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2.
     Cell. 2020;182:50-58.
     PubMed     Abstract available
     
     
     
179. SHEN B, Yi X, Sun Y, Bi X, et al
     Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.
     Cell. 2020;182:59-72.
     PubMed     Abstract available
     
     
     
180. CAO Y, Su B, Guo X, Sun W, et al
     Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.
     Cell. 2020;182:73-84.
     PubMed     Abstract available
     
     
     
181. JOYCE MG, Wheatley AK, Modjarrad K
     Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.
     Cell. 2020;182:7-9.
     PubMed     Abstract available
     
     
     June 2020
182. SEMPOWSKI GD, Saunders KO, Acharya P, Wiehe KJ, et al
     Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.
     Cell. 2020;181:1458-1463.
     PubMed     Abstract available
     
     
     
183. BOST P, Giladi A, Liu Y, Bendjelal Y, et al
     Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients.
     Cell. 2020;181:1475-1488.
     PubMed     Abstract available
     
     
     
184. GRIFONI A, Weiskopf D, Ramirez SI, Mateus J, et al
     Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
     Cell. 2020;181:1489-1501.
     PubMed     Abstract available
     
     
     
185. ZEGGINI E, Baumann M, Gotz M, Herzig S, et al
     Biomedical Research Goes Viral: Dangers and Opportunities.
     Cell. 2020;181:1189-1193.
     PubMed     Abstract available
     
     
     
186. ZHANG K, Liu X, Shen J, Li Z, et al
     Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography.
     Cell. 2020;181:1423-1433.
     PubMed     Abstract available
     
     
     
187. CASANOVA JL, Su HC
     A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection.
     Cell. 2020;181:1194-1199.
     PubMed     Abstract available
     
     
     May 2020
188. NETEA MG, Giamarellos-Bourboulis EJ, Dominguez-Andres J, Curtis N, et al
     Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection.
     Cell. 2020;181:969-977.
     PubMed     Abstract available
     
     
     
189. BLANCO-MELO D, Nilsson-Payant BE, Liu WC, Uhl S, et al
     Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.
     Cell. 2020;181:1036-1045.
     PubMed     Abstract available
     
     
     
190. ZIEGLER CGK, Allon SJ, Nyquist SK, Mbano IM, et al
     SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.
     Cell. 2020;181:1016-1035.
     PubMed     Abstract available
     
     
     
191. FAUVER JR, Petrone ME, Hodcroft EB, Shioda K, et al
     Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States.
     Cell. 2020;181:990-996.
     PubMed     Abstract available
     
     
     
192. WRAPP D, De Vlieger D, Corbett KS, Torres GM, et al
     Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
     Cell. 2020;181:1004-1015.
     PubMed     Abstract available
     
     
     
193. LU J, du Plessis L, Liu Z, Hill V, et al
     Genomic Epidemiology of SARS-CoV-2 in Guangdong Province, China.
     Cell. 2020;181:997-1003.
     PubMed     Abstract available
     
     
     
194. HOU YJ, Okuda K, Edwards CE, Martinez DR, et al
     SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.
     Cell. 2020 May 27. pii: S0092-8674(20)30675-9. doi: 10.1016/j.cell.2020.
     PubMed     Abstract available
     
     
     
195. OBERFELD B, Achanta A, Carpenter K, Chen P, et al
     SnapShot: COVID-19.
     Cell. 2020;181:954-954.
     PubMed     Abstract available
     
     
     
196. MONTEIL V, Kwon H, Prado P, Hagelkruys A, et al
     Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
     Cell. 2020;181:905-913.
     PubMed     Abstract available
     
     
     April 2020
197. ABBOTT TR, Dhamdhere G, Liu Y, Lin X, et al
     Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
     Cell. 2020 Apr 29. pii: S0092-8674(20)30483-9. doi: 10.1016/j.cell.2020.
     PubMed     Abstract available
     
     
     
198. WANDZIK JM, Kouba T, Karuppasamy M, Pflug A, et al
     A Structure-Based Model for the Complete Transcription Cycle of Influenza Polymerase.
     Cell. 2020 Apr 16. pii: S0092-8674(20)30389-5. doi: 10.1016/j.cell.2020.
     PubMed     Abstract available
     
     
     
199. 
     COVID-19: Navigating Uncertainties Together.
     Cell. 2020;181:209-210.
     PubMed    
     
     
     
200. ZHANG YZ, Holmes EC
     A Genomic Perspective on the Origin and Emergence of SARS-CoV-2.
     Cell. 2020;181:223-227.
     PubMed     Abstract available
     
     
     
201. HOFFMANN M, Kleine-Weber H, Schroeder S, Kruger N, et al
     SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
     Cell. 2020;181:271-280.
     PubMed     Abstract available
     
     
     March 2020
202. ZHANG T, Yin C, Boyd DF, Quarato G, et al
     Influenza Virus Z-RNAs Induce ZBP1-Mediated Necroptosis.
     Cell. 2020;180:1115-1129.
     PubMed     Abstract available
     
     
     
203. 
     The Novel Coronavirus Outbreak: What We Know and What We Don't.
     Cell. 2020;180:1034-1036.
     PubMed    
     
     
     January 2020
204. VAHEY MD, Fletcher DA
     Low-Fidelity Assembly of Influenza A Virus Promotes Escape from Host Cells.
     Cell. 2020;180:205.
     PubMed    
     
     
     May 2019
205. GARCIA-SASTRE A
     Snatch-and-Grab Inhibitors to Fight the Flu.
     Cell. 2019;177:1367.
     PubMed     Abstract available
     
     
     January 2019
206. MARTIN BE, Brooke CB
     Flu Shows the Power of Diversity.
     Cell. 2019;176.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: